Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

Core Insights - Daxor Corporation intends to transition its primary regulatory reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, reflecting the company's growth and strategic maturation in its core diagnostic technology business [1][4] Company Focus - The principal focus of Daxor remains on the development and commercialization of its Blood Volume Analysis (BVA) technology, which is the only FDA-cleared diagnostic blood test that provides objective, patient-specific quantification of total blood volume status and composition [2] Key Highlights of the Transition - The transition back to Exchange Act reporting is seen as a financial validation of Daxor's growth strategy, aligning regulatory and operational frameworks with its identity as a high-growth medical diagnostic company [4] - The company anticipates completing the necessary regulatory steps to effectuate the change in reporting status by the end of the second quarter, pending required regulatory filings and approvals [4] Operational and Financial Alignment - The transition validates the success of management's strategy to prioritize and rapidly grow the BVA technology division, marked by revenue increases and new customer acquisitions [8] - The company's financial profile is now more accurately represented under the Exchange Act framework, aligning its regulatory status with its identity as an innovative medical device and diagnostic technology firm [8] Enhanced Investor Clarity - Reporting under the Exchange Act will simplify financial disclosures, providing standardized GAAP metrics and benchmarks comparable to other publicly traded medical diagnostic companies, which is expected to improve transparency and attract deeper institutional interest [8]